<DOC>
	<DOCNO>NCT00526292</DOCNO>
	<brief_summary>The goal study see benefit give chemotherapy natural killer ( NK ) cell . The NK cell must come family member share half patient HLA protein . NK cell type white blood cell . They recognize kill abnormal cell body . Patients whose blood cancer cure stem cell transplant standard treatment option . Studies show NK cell donor give safely helpful treat blood disease . These NK cell collect patient donor purify use separation system call CliniMACS use safely previous study use study approval Federal Food Drug Administration . The researcher want find effect NK cell blood cancer bone marrow function maximize benefit treat blood cancer . The researcher hope give chemotherapy NK cell well treatment disease current available treatment option . Funding Source - Food Drug Administration/Office Orphan Products Development</brief_summary>
	<brief_title>Chemotherapy Donor Natural Killer Cell Infusion Treating Patients With Relapsed Persistent Leukemia Myelodysplastic Syndrome After Donor Stem Cell Transplant</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine anti-leukemic efficacy allogeneic HLA-haploidentical related natural killer ( NK ) cell infusion follow cytoreductive regimen cyclophosphamide fludarabine patient acute myeloid leukemia ( AML ) , myelodysplastic syndrome ( MDS ) , blastic CML relapse follow allogeneic hematopoietic stem cell transplant , efficacy define achievement complete partial remission one year follow NK cell infusion . Secondary - To assess treatment efficacy , define achievement complete partial remission , 3 6 month follow HLA-haploidentical related NK cell infusion . - To assess effect HLA-haploidentical related NK cell infusion sustain engraftment recovery HLA-matched stem cell allograft . - To assess risk induce graft-vs-host disease ( GVHD ) alter severity . - To provide preliminary evidence specific donor KIR-recipient HLA ligand combination relate miss self-MHC class I ligand miss class I ligand associate high NK alloreactivity improve outcome . - To monitor extent duration NK cell donor chimerism . - To monitor NK cell reconstitution NK receptor cell surface phenotyping ( CD94/NKG2A , ILT-2 , KIR expression ) function ( intracellular IFN-γ , cytotoxicity ) day 15 , 30 , 60 , 100 , 200 follow NK infusion correlate outcome . - To correlate magnitude NK effect disease know survival risk factor ( time allogeneic HSCT relapse ; &lt; 6 month vs &gt; 6 month ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Subject Diagnosis Status Patients pathologically confirm diagnosis relapse persistent resistant AML , MDS , blastic CML follow HSCT deem ineligible second HSCT consideration adequacy physical function , extent disease , prior treatmentrelated toxicity . Eligible patient evidence disease ≥5 % bone marrow involvement detect morphology abnormal cytogenetics ( karyotype FISH ) . Patients molecular detection marker characteristic patient 's disease two consecutive bone marrow biopsy also eligible . Following diagnosis relapse disease , treatment reduce leukemic burden allow prior protocol therapy without need additional disease documentation prior cyclophosphamide fludarabine . Patients extramedullary relapse eligible except CNS involvement . Patients must receive allogeneic HSCT . Patient must pregnant must use adequate form birth control . Patients must Karnofsky ( adult ) Lansky ( pediatric ) Performance Status ≥ 60 % . Hospitalization preclude enrollment , long patient 's performance status ≥ 60 % accord KPS grade scale . Patients must adequate physical function measure : Cardiac : asymptomatic LVEF rest must &gt; 50 % . Hepatic : &lt; 2x ULN ALT &lt; 1.5 total serum bilirubin , unless liver involved disease , congenital benign hyperbilirubinemia , reversible cause hepatic abnormality document . Renal : serum creatinine &lt; 1.5 mg/dl serum creatinine outside normal range , CrCl &gt; 50 ml/min Pulmonary : Patient oxygendependent . Patients document GVHD exclude trial , either must use systemic immunosuppression two week , immunosuppression taper document two subtherapeutic level least one week apart . Immunosuppressive agent include limited systemic steroid , calcineurin inhibitor , MTORinhibitors , Budesonide , antithymocyte globulin . The maximal allowable dose corticosteroid equivalent 10 mg/day prednisone . Patients grade I/II acute GVHD limit chronic GVHD receive localize GVHD therapy ( e.g . topical steroid ) exclude trial . Patients receive previous adoptive cellular therapy donor lymphocyte infusion ( DLI ) exclude trial long disease document progress within two month receive DLI patient receive DLI within two month NK cell infusion . Patients receive cytoreductive therapy follow documentation relapse prior enrollment exclude trial . The interval standard reinduction chemotherapy start protocol chemotherapy minimum 2 week , induction chemotherapyrelated toxicity document completely resolve . For patient receive nonintensive chemotherapy hydroxyurea lowdose cytarabine , nonintensive chemotherapy discontinue upon initiation protocol chemotherapy . Each patient must willing participate research subject must sign informed consent form . Parents legal guardian patient minor may sign informed consent form Patients must eligible NK donor . There age restriction protocol . NK Cell Donor Eligibility Donor bloodrelated HLAhaploidentical recipient . Donor undergone serologic test transmissible disease per blood banking guideline organ tissue donor . Tests include limited : HepBsAg , HepBsAb , HepBcAb , HepC antibody , HIV , HTLV I II , VZV , CMV VDRL , West Nile Virus . Donor must normal negative test result HIV , HTLV I II , West Nile Virus . Donor exposure viral pathogen discuss casebycase basis Transplant team . Donor CXR EKG perform . Donor must able undergo leukopheresis total volume 1015 liter . Donor pregnant . Donor concurrent malignancy autoimmune disease . There age restriction donor . Subject Patients systemic immunosuppression therapeutic drug level . Patients whose immunosuppression actively taper documentation subtherapeutic drug level one week apart exclude enrollment . For patient receive corticosteroid , maximal allowable dose corticosteroid equivalent 10 mg/day prednisone . Patients untreated uncontrolled active infection . Infections control appropriately treat exclude patient enrollment . NK Cell Donor Exclusion Donor cardiac risk factor preclude ability undergo leukopheresis . Donor evidence concurrent malignancy autoimmune disease . Donor pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
</DOC>